

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

**VOLUNTARY ANNOUNCEMENT –
COMPLETION OF FIRST PATIENT DOSING IN THE PHASE III
CLINICAL TRIAL OF JS203 IN COMBINATION WITH CHEMOTHERAPY
FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA**

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) on a voluntary basis. Reference is also made to the overseas regulatory announcement of the Company dated 23 October 2026.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, first patient dosing has been completed in a randomized, open-label, multicenter phase III clinical study of the Company’s product, a recombinant humanized anti-CD20/CD3 bispecific antibody (code: JS203), in combination with chemotherapy compared to rituximab in combination with chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (“**DLBCL**”) (the “**JS203-003-III-DLBCL Study**”; NCT07808827). This study is the first registrational clinical study for JS203.

ABOUT JS203

JS203 is a recombinant humanized anti-CD20/CD3 bispecific antibody self-developed by the Company. CD20 is a B lymphocyte restricted differentiation antigen and one of the most successful targets for B-cell lymphoma treatment. CD3 is an important marker on the surface of T cells, and the main mechanism of T cell engaging bispecific antibodies is using CD3 as a mediator to activate T cells to specifically attack tumor cells. JS203 consists of anti-CD20 segments and an anti-CD3 segment. By associating and activating lymphoma cells (binding to CD20) and T cells (binding to CD3), JS203 can enable T cells to kill lymphoma cells effectively. Pre-clinical in vivo pharmacodynamics studies show that JS203 has a significant anti-tumor effect. In addition, JS203 is well tolerated by animals.

In April 2025, preliminary results from a phase I clinical study of JS203 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) were presented in the form of poster presentation (Abstract No.: #CT025) for the first time at the AACR Annual Meeting. The results showed that, after pretreatment with rituximab, JS203 administered with step-up dosing (SUD) demonstrated a good overall safety profile. JS203 demonstrated promising anti-tumor efficacy in patients with CD20-positive relapsed or refractory B-cell non-Hodgkin lymphoma, with efficacy signals observed in the group with lower dose. In particular, among patients with DLBCL treated with JS203 at 30 mg, the objective response rate (“**ORR**”) reached 80%, and the complete response rate (“**CRR**”) was 40%. Due to limited follow-up time, the median duration of response (DoR) has not yet been reached, demonstrating the therapeutic potential of JS203 in patients with CD20-positive relapsed or refractory B-cell non-Hodgkin lymphoma, and JS203 is expected to provide a potential new treatment option for patients with malignant lymphoma.

In December 2025, updated results from the phase I clinical study of JS203 for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma were presented in the form of poster presentation (Abstract No.: #1957) at the 67th Annual Meeting of the American Society of Hematology (ASH). The results showed that, for JS203 monotherapy at the recommended phase II dose (RP2D) administered with SUD to 30 mg for the treatment of patients with CD20-positive relapsed or refractory B-cell non-Hodgkin lymphoma, the ORR reached 72.4%. Among patients with DLBCL, the ORR was 69.7%, and the CRR was 39.4%, with durable responses observed. Meanwhile, the overall safety profile was manageable, with a cytokine release syndrome (CRS) incidence rate of only 27.3% and no occurrence of immune effector cell-associated neurotoxicity syndrome (ICANS).

ABOUT THE JS203-003-III-DLBCL STUDY

DLBCL is one of the most common types of non-Hodgkin lymphoma (NHL), accounting for approximately 40% of adult NHL cases in China. According to GLOBOCAN 2022 statistics, there are approximately 45,000 new cases of DLBCL in China each year, and the incidence rate shows a slow increasing trend. DLBCL is characterized by high aggressiveness and rapid progression. A retrospective study in an Asian population showed that, even after active treatment, patients with relapsed or refractory DLBCL had a median overall survival (mOS) of over one year and a 5-year survival rate of approximately 30%, which necessitates the exploration of more proactive and effective treatment options.

The JS203-003-III-DLBCL Study is a randomized, open-label, multicenter phase III clinical trial, with Professor Song Yuqin (宋玉琴) of Beijing Cancer Hospital (北京腫瘤醫院) serving as the principal investigator. It aims to compare the efficacy and safety of JS203 in combination with chemotherapy compared to rituximab in combination with chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma. The study plans to enroll 282 subjects, with overall survival (OS) as its primary endpoint. This study is the first registrational clinical study for JS203.

RISK WARNING

Due to the high-tech, high-risk and high value-added characteristics of pharmaceutical products, the preliminary research and development of drugs and the process spanning from product development, clinical trial application and approval to commercial production are lengthy and involve multiple stages, and are susceptible to the impact of certain uncertainties. Investors are therefore advised to make cautious decisions and pay careful attention to investment risks. The Company will actively pursue the above research and development project and fulfill its information disclosure obligations in a timely manner for subsequent progress in strict compliance with relevant regulations.

By order of the Board of
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 23 October 2026

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Wang Gang and Dr. Li Xin as executive Directors; Dr. Yao Sheng and Mr. Tang Yi as non-executive Directors; and Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun, Dr. Yang Jin and Mr. Chen Liang as independent non-executive Directors.

* *For identification purpose only*